In:
Clinical Transplantation, Wiley, Vol. 26, No. 5 ( 2012-09), p. 679-683
Abstract:
Chan TSY, Hwang Y‐Y, Gill H, Au W‐Y, Leung AYH, Tse E, Chim C‐S, Loong F, Kwong Y‐L. Post‐transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment. Abstract: Nineteen consecutive patients with post‐transplant lymphoproliferative disorders (PTLD) in an Asian population were reviewed. The histopathologic diagnoses were monomorphic (CD20‐positive diffuse large B‐cell lymphoma, n = 14); plasmacytic (n = 1); Burkitt‐like (n = 1); natural killer cell lymphoma (n = 1); lymphomatoid papulosis (n = 1); and classical Hodgkin lymphoma (n = 1). Early‐onset ( 〈 one yr post‐transplantation) PTLD constituted only 10% of cases, and all were Epstein–Barr virus (EBV) positive. EBV‐negative cases (n = 6) developed at a median of 92 (19–170) months, whereas EBV‐positive cases occurred later at 128 (7–230) months. With reduction of immunosuppression followed by local therapy, treatment with the anti‐CD20 antibody rituximab with or without combination chemotherapy, complete remission was achieved in 17/19 (90%) of cases. Lactate dehydrogenase level, stage, extranodal involvement, EBV status, and International Prognostic Index had no impact on treatment outcome. EBV‐positive PTLD occurred much later in Asian patients. Treatment results of PTLD were favorable.
Type of Medium:
Online Resource
ISSN:
0902-0063
,
1399-0012
DOI:
10.1111/ctr.2012.26.issue-5
DOI:
10.1111/j.1399-0012.2011.01593.x
Language:
English
Publisher:
Wiley
Publication Date:
2012
detail.hit.zdb_id:
2739458-X
detail.hit.zdb_id:
2004801-4
Permalink